Designed to improve proficiency in interpreting Claudin-18.2 (CLDN18.2) expression, a biomarker increasingly relevant in gastric and gastroesophageal cancers2.
An independent, not‑for‑profit community interest company based in the UK
Focused on improving the quality and accuracy of cancer diagnostic (biomarker) testing, particularly in pathology
Overview
Introductory module (optional | on demand)
Updates, interpretation guidance, and practical scoring approaches
Qualification test (online)
Opens: June 15, 2026 | Closes: July 6, 2026
Up to 6 cases
After completion: summary of results, including comparison with your peers
Live case discussion (optional)
8, July 2026, 3:00 PM BST
Interactive discussion of cases and Q&A
Click here or Scan for registration
1. Röcken, C. et al. Virchows Arch 487, 1117–1125 (2025).
2. Fassan, M. et al. Mod Pathol. 2024 Nov;37(11):100589.